Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population
2
조회
0
다운로드
23
인용
0
참고문헌
키워드
초록
The B-type Raf kinase (BRAF) protein is a serine/threonine kinase that has an important role in cellular proliferation, differentiation, and programmed cell death. The BRAF gene has been recently found to be mutated in human carcinomas, predominantly in malignant melanoma. The aim of this study was to investigate the frequency of the BRAF mutation in papillary thyroid carcinoma (PTC) of Koreans through direct DNA sequencing of the polymerase chain reaction (PCR)- amplified exon 15 with clinicopathological features. Seventy paraffin-embedded conventional papillary carcinomas in the thyroid gland were evaluated. The BRAF missense mutation at V599E was found in 58 of 70 PTCs (83%). The frequency of our series was much higher than the frequencies of other PTC series (36-69%). The frequency of nodal metastasis was also significantly higher in the BRAF mutation group(p= 0.048). These results suggest that the BRAF mutation is involved in the carcinogenesis in most conventional PTCs, especially those occurring in Koreans, and this is a potentially valuable marker for the evaluation of prognosis of patients with PTC. These findings support the specific inhibitors of BRAF being promising targets for the disease outcome.
Abstract
The B-type Raf kinase (BRAF) protein is a serine/threonine kinase that has an important role in cellular proliferation, differentiation, and programmed cell death. The BRAF gene has been recently found to be mutated in human carcinomas, predominantly in malignant melanoma. The aim of this study was to investigate the frequency of the BRAF mutation in papillary thyroid carcinoma (PTC) of Koreans through direct DNA sequencing of the polymerase chain reaction (PCR)- amplified exon 15 with clinicopathological features. Seventy paraffin-embedded conventional papillary carcinomas in the thyroid gland were evaluated. The BRAF missense mutation at V599E was found in 58 of 70 PTCs (83%). The frequency of our series was much higher than the frequencies of other PTC series (36-69%). The frequency of nodal metastasis was also significantly higher in the BRAF mutation group(p= 0.048). These results suggest that the BRAF mutation is involved in the carcinogenesis in most conventional PTCs, especially those occurring in Koreans, and this is a potentially valuable marker for the evaluation of prognosis of patients with PTC. These findings support the specific inhibitors of BRAF being promising targets for the disease outcome.
참고문헌 (23)
- "Thyroid cancer", 163, pp.143~156 (2001)
- "High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET", PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, 2003, pp.63, 1454~1457
- "BRAF mutation in papillary thyroid carcinoma", 95, pp.625~627 (2003)
- "BRAF mutations and RET", PTC rearrangements are alternative events in the etiopathogenesis of PTC, 2003, pp.22, 4578~4580
- "High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines", 63, pp.4561~4567 (2003)
- "The Raf", MEK, pp.200193[DOI]
- "Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade", 56, pp.127~155 (2001)
- "Meaningful relationships: the regulation of the Ras", Raf, ERK pathway by protein interactions, 2000[DOI]
- "Raf proteins and cancer: B-Raf is identified as a mutational target", 1653, pp.25~40 (2003)
- "B-raf and a B-raf pseudogene are located on 7q in man", 7, pp.795~799 (1992)
- "Mutations of the BRAF gene in human cancer", 417, pp.949~954 (2002)
- "Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia", 62, pp.6451~6455 (2002)
- "Tumorigenesis: RAF", RAS oncogenes and mismatch-repair status, 2002, pp.418, 934~
- "BRAF mutations are associated with some histological types of papillary thyroid carcinoma", 202, pp.247~251 (2004)
- "BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment", 11 (2004)
- "Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype", 89, pp.1517~1522 (1992)
- "Detection of the PTC", retTPC oncogene in human thyroid cancers, 1992, pp.7, 1331~1337
- "Specific pattern of RAS oncogene mutations in follicular thyroid tumors", 88, pp.2745~2752 (2003)
- "Medullary thyroid cancer", 36, pp.91~105 (2003)
- "Molecular biology of thyroid neoplasms", 25, pp.151~161 (2000)
- "BRAF T1796A transversion mutation in various thyroid neoplasms", 89, pp.1365~1368 (2004)
- "BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas", 444, pp.572~576 (2004)
- "BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas", 88, pp.5399~5404 (2003)